High Intensity Body-weight Circuit Training Feasibility and Efficacy for in Middle Aged Persons With Type 2 Diabetes
NCT05571384
Recruiting
This research study proposes to quantify the efficacy of the novel high intensity body-weight circuit (HIBC) training intervention on metabolic profile, body composition, and health related fitness exercise in middle aged persons with type-2 diabetes (T2DM). This research project is extremely relevant to public health, in that prevalence of T2DM continues to rise on a national and global scale, placing a heavy economic cost on both the healthcare industry and the individual patient in an age-dep... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
03/25/2025
Locations: Kennesaw State Univeristy, Kennesaw, Georgia
Conditions: Type2diabetes
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +565 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
NCT05711615
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida +13 locations
Conditions: Metastatic Leiomyosarcoma, Metastatic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Sarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Myxofibrosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Myxofibrosarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia
NCT05828108
Recruiting
Background: Diamond-Blackfan anemia (DBA) is an inherited disease that affects the bone marrow. People with DBA have chronic anemia that can be severe. Many must have frequent transfusions of red blood cells. Current treatments for DBA all have risks of serious side effects. Better treatments are needed. Objective: To test a new drug (bitopertin) in people with DBA. Eligibility: People aged 18 or older with DBA. Design: Participants will be screened. They will have a physical exam; they w... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA)
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Neumora Investigator site, Huntsville, Alabama +149 locations
Conditions: Major Depressive Disorder
Register for Updates
Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer
NCT06127836
Recruiting
The purpose of this study is to compare two types of imaging for sentinel lymph node (SLN) mapping in people with early-stage vulvar cancer. The researchers will compare indocyanine green near-infrared (ICG-NIR) imaging with lymphoscintigraphy. All participants in this study will be scheduled for standard surgical treatment at Memorial Sloan Kettering Cancer Center (MSK). This surgical treatment includes SLN mapping (with both lymphoscintigraphy and ICG-NIR imaging) and SLN biopsy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +7 locations
Conditions: Vulvar Cancer
Register for Updates
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
NCT06230510
Recruiting
In the U.S. it is recommended that children consume whole cow's milk (3.5% fat) from ages 1 to 2 years to support rapid early growth and brain development, and then at age 2 years transition to low-fat (1%) or non-fat milk to reduce saturated fat and calorie intake. To date, few studies have examined the optimal milk type for children to prevent obesity. This randomized controlled trial will evaluate the effect of consumption of whole versus 1% milk on child adiposity.
Gender:
ALL
Ages:
Between 23 months and 48 months
Trial Updated:
03/25/2025
Locations: Nutrition Policy Institute, University of California Agriculture and Natural Resources, Oakland, California
Conditions: Obesity
Register for Updates
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
NCT06303180
Recruiting
Background: Many disorders of the head and neck can affect a person s hearing; balance; smell; taste; swallowing; voice; or speech. These disorders include cancers and genetic and inflammatory diseases. To find better ways to diagnose and treat these disorders, researchers need to study tissues and other biological samples from people who have them. Objective: To collect biological samples for a repository that will be used for research. Eligibility: People of any age with a disorder of the... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
03/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hearing Loss, Head and Neck Neoplasms, Hearing Disorders, Laryngeal Disease
Register for Updates
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
NCT06362265
Recruiting
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/25/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona +10 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Katmai Oncology Group - Anchorage, Anchorage, Alaska +36 locations
Conditions: Breast Cancer
Register for Updates
Iterative Redesign of a Multifaceted Implementation Strategy for a School-based Behavioral Skills Intervention (RUBI)
NCT06508515
Recruiting
The increased prevalence of autism spectrum disorder (1 in 36 youth) in the United States along with the exorbitant cost of care of supporting one autistic individual with and without intellectual disability across their lifespan ($2.4 and $1.4 million, respectively) creates a sense of urgency to improve outcomes for autistic youth. Schools are the primary setting in which autistic children receive intervention. Despite a growing array of evidence-based interventions (EBI) such as behavioral man... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
03/25/2025
Locations: University of Washington, Seattle, Washington
Conditions: Autism Spectrum Disorder
Register for Updates
Improving Congenital Heart Disease Care
NCT06581484
Recruiting
The theory-informed digital health intervention, called as "Empower My Congenital Health (EmpowerMyCH)" aims to activate and engage ACHD patients in building confidence toward navigating the adult healthcare system. This tool is built after incorporating the theories of behavior change, gathering inputs from target patients in all stages of its design and implementation. The key features of the tool include a digital medical passport, updated congenital information, community support, and patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Congenital Heart Disease, Behavior, Health, Quality of Life, Empowerment, Patient, Activation, Patient
Register for Updates